ABCAM appoints Mara Aspinall to its Board as Non-Executive Director

– UK, Cambridge – Abcam announces the appointment of Mara Glickman Aspinall (53) to the Board of Abcam as a Non-Executive Director, with immediate effect.

A biotech industry leader, Mara was the President and CEO of Ventana Medical Systems, the Tissue Diagnostics Division of The Roche Group. While at Ventana, she led the company to increased market leadership worldwide and primacy in companion diagnostics. Previously, Mara spent twelve years at Genzyme Corporation (now part of Sanofi) where she was the President of Genzyme Genetics and Genzyme Pharmaceuticals. She was also the Founder and CEO of On-Q-ity, a circulating tumour cells company.

Mara currently serves as Executive Chairman of GenePeeks Inc.; Director of Safeguard Scientifics (NYSE: SFE), Castle Biosciences and Blue Cross Blue Shield Arizona.

Mara is a Co-Founder of EPEMED (European Personalized Medicine Association) and the International School of Biomedical Diagnostics at Arizona State University and Dublin City University, the only school dedicated to the study of diagnostics as an independent discipline. She is a fellow of the American Institute for Medical and Biological Engineering. Mara holds an MBA from Harvard Business School and a BA in International Relations from Tufts University.

Murray Hennessy, Chairman of Abcam, commented: “We are delighted to further strengthen our Board by welcoming Mara to Abcam. Mara’s vast expertise in the diagnostics and pharma industries at Ventana and Genzyme, and her knowledge of and experience within the US market, will be invaluable as we continue to expand our business and deliver value to our shareholders.”

About Abcam

Abcam plc is a provider of life science research tools, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level and improving the understanding of health and disease.

Abcam is committed to providing scientists with an extensive choice of reagents and tools, with the most comprehensive, honest and up-to-date datasheets and customer reviews, fast delivery and helpful customer service & technical support. The Company’s catalogue evolves with scientific research trends and is growing each year to provide customers with products to meet their research needs. The range now includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam also supports its customers by hosting a range of global scientific events, forums and webinars, providing opportunities for scientists to get together and present their work.

Headquartered in Cambridge, UK, Abcam has nine global subsidiary offices enabling local services, multi-language support and next-day delivery in over 130 countries. The Company was founded in 1998, and now employs over 820 people. Abcam was admitted to AIM in 2005 (AIM:ABC).

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

here, the original post =>